Australia markets open in 8 hours 3 minutes

ABBV May 2022 110.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
1.5700-0.1200 (-7.10%)
As of 09:32AM EST. Market open.
Full screen
Previous close1.6900
Open1.5700
Bid1.3500
Ask1.8200
Strike110.00
Expiry date2022-05-20
Day's range1.5700 - 1.5700
Contract rangeN/A
Volume15
Open interest2.64k
  • PR Newswire

    Allergan Aesthetics Announces Open Casting Call for BOTOX® Cosmetic (onabotulinumtoxinA)

    Allergan Aesthetics, an AbbVie company (NYSE: ABBV) announced today it will be hosting an open casting call seeking people who would like to share their BOTOX® Cosmetic Story. The company continues its commitment to showcase real people and real stories as part of its larger mission to create a more inclusive and authentic dialogue around the decision to receive aesthetic treatments. Building on the success of the original 'See Yourself' campaign, launched in 2021, BOTOX® Cosmetic, is launching

  • Motley Fool

    3 No-Brainer Healthcare Stocks to Buy Right Now for Less than $150

    Not only is the price right for these three healthcare stocks, but they all offer revenue growth along with an above-average dividend.

  • Motley Fool

    What This FDA News Could Mean for AbbVie's Stock

    Earlier this month, AbbVie (NYSE: ABBV) completed its application to the U.S. Food and Drug Administration (FDA) for Rinvoq to treat adults with a back arthritis (known as non-radiographic axial spondyloarthritis) who previously tried nonsteroidal anti-inflammatory drugs (NSAIDs) but did not benefit. If eventually approved by the FDA, this would be the fourth approved indication in the U.S. for Rinvoq. Let's take a look at Rinvoq's efficacy in treating patients with this form of back arthritis and the sales potential of the indication for pharma stock AbbVie.